32 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
on the same proprietary molecule as CC8464, the Company’s newly launched program, titled CT2000, is for the potential treatment of both acute and chronic … if it is ultimately determined that we will need an escalation period for chronic pain treatment therapy, which patients could well take for the remainder
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
on the same proprietary molecule as CC8464, the Company’s newly launched program, titled CT2000, is for the potential treatment of both acute and chronic … if it is ultimately determined that we will need an escalation period for chronic pain treatment therapy, which patients could well take for the remainder
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
, the Company’s newly launched program, titled CT2000, is for the potential treatment of both acute and chronic eye pain. NaV1.7 receptor is present on the cornea … will allow us to better understand the pharmacokinetics of CC8464. Even if it is ultimately determined that we will need an escalation period for chronic pain
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
condition with associated nerve damage in the hands and feet. Neither EM nor iSFN have currently approved treatments.
Acute and chronic eye pain resulting … revenue. According to data published by the Centers for Disease Control and Prevention (“CDC”), in 2019, 20.4% of adults had chronic pain, and 7.4
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
condition with associated nerve damage in the hands and feet. Neither EM nor iSFN have currently approved treatments.
Acute and chronic eye pain resulting … revenue. According to data published by the Centers for Disease Control and Prevention (“CDC”), in 2019, 20.4% of adults had chronic pain, and 7.4
10-K
mtg45
16 Apr 24
Annual report
4:48pm
8-K
EX-99.1
p643b4aub
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
8-K
EX-99.1
bg2y9
21 Mar 24
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
9:00am
8-K
EX-99.1
xa8q5szqthb6vqa6j
18 Mar 24
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
4:05pm
8-K
EX-99.1
nzyzwy3d6l t4gzmldc9
13 Mar 24
Regulation FD Disclosure
8:00am
8-K
5rfj0 2vfk6d5db2n9l
13 Mar 24
Regulation FD Disclosure
8:00am
8-K
EX-99.1
i06p6 eax56p2obnxzp9
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-99.2
m3dxcxmbcqgexem
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
prm0jgx2199
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
spqetq1
20 Feb 24
Prospectus supplement with pricing info
5:28pm
FWP
gujnt5h0b
12 Feb 24
Free writing prospectus
8:09am
FWP
zhcrh4wf3 aydw
6 Feb 24
Free writing prospectus
8:43pm